Table 1. T-LGLL Patient Clinical Data Summary.
Fresh PBMCs were obtained from five T-LGLL patients for use in qPCR studies. Inclusion criteria are described in the materials and methods section. Relevant clinical information is included in this table.
| Patient # | Sex | Age | TCR | CD3+CD8+ purity (%) | ANC | STAT3 Mutation Status | Treatment |
|---|---|---|---|---|---|---|---|
| 1 | F | 68 | αβ | 30* | 2459 | Y640F | None |
| 2 | M | 73 | αβ | 81 | 1800 | WT | None |
| 3 | F | 29 | 77% αβ, 7% γδ | 48 | 460 | WT | None |
| 4 | M | 52 | αβ | 93 | 1200 | Y640F | None, previously on methotrexate/cyclophosphamide |
| 5 | F | 69 | αβ | 42 | 2500 | WT | None, previously on cyclosporine/methotrexate/Neupogen |
*
CD3+CD8+CD7− instead of CD3+CD8+